# Pelthos Therapeutics Inc.: overview

PTHS · NYSE · CIK 1919246 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pths.md) · [Financials](/companies/pths/financials.md) · [Filings](/companies/pths/filings.md) · [Insiders](/companies/pths/insiders.md)

Latest reported revenue: [$15.6m](/filings/0001919246-26-000113.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001919246-26-000113).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001919246-26-000111.md) | [0.0](/filings/0001919246-26-000113.md) | [0.3](/filings/0001753926-25-001764.md) | [16.5 d](/filings/0001919246-26-000013.md) | [10.9](/filings/0001919246-26-000111.md) | [15.6](/filings/0001919246-26-000113.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | [(5225.2%)](/filings/0001753926-25-001764.md) | [(72.7%) d](/filings/0001919246-26-000013.md) | [(120.0%)](/filings/0001919246-26-000111.md) | [(111.0%)](/filings/0001919246-26-000113.md) |
| Net margin | % | not reported | not reported | not reported | not reported | [(5523.1%)](/filings/0001753926-25-001764.md) | [(131.3%) d](/filings/0001919246-26-000013.md) | [(229.9%)](/filings/0001919246-26-000113.md) | [(150.1%)](/filings/0001919246-26-000113.md) |
| Diluted EPS | $ per share | [(2.93)](/filings/0001753926-25-001764.md) | not reported | [(3.21)](/filings/0001919246-26-000111.md) | [(5.29)](/filings/0001919246-26-000113.md) | [(5.30)](/filings/0001753926-25-001764.md) | not reported | [(7.57)](/filings/0001919246-26-000111.md) | [(6.62)](/filings/0001919246-26-000113.md) |
| Free cash flow | $m | not reported | not reported | [(0.6)](/filings/0001919246-26-000111.md) | [(0.4) d](/filings/0001919246-26-000113.md) | not reported | not reported | [(13.3)](/filings/0001919246-26-000111.md) | [(7.7) d](/filings/0001919246-26-000113.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001919246-26-000013.md) | [16.8](/filings/0001919246-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | [(193.1%)](/filings/0001919246-26-000013.md) |
| Net margin | % | not reported | not reported | not reported | [(257.9%)](/filings/0001919246-26-000013.md) |
| Diluted EPS | $ per share | not reported | [(5.78)](/filings/0001753926-25-000503.md) | [(14.27)](/filings/0001919246-26-000013.md) | [(23.04)](/filings/0001919246-26-000013.md) |
| Free cash flow | $m | not reported | not reported | [(5.8)](/filings/0001919246-26-000013.md) | [(22.7)](/filings/0001919246-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pths/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [AIGH Capital Management LLC](/funds/1835943.md) | 2026-06-30 | $9.3m | 329,098 |  | New +329,098 |
| [Murchinson Ltd.](/funds/1838556.md) | 2026-06-30 | $8.6m | 304,302 |  | Added +7,988 |
| [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $7.3m | 256,598 |  | Unchanged |
| [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $2.9m | 101,976 |  | Added +20,118 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.7m | 97,134 |  | Added +4,041 |
| [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $1.1m | 38,123 |  | Reduced −3,300 |
| [CANTOR FITZGERALD, L. P.](/funds/1024896.md) | 2026-06-30 | $1.1m | 38,123 |  | Reduced −3,300 |
| [J. Goldman & Co LP](/funds/1412741.md) | 2026-06-30 | $1.1m | 38,075 |  | Reduced −12,340 |
| [DIADEMA PARTNERS LP](/funds/2026172.md) | 2026-06-30 | $700.1k | 24,773 |  | Unchanged |
| [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $632.0k | 22,364 |  | New +22,364 |

## Recent filings

[All 243 filings](/companies/pths/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-01 | 21:15 ET | [8-K](/filings/0001919246-26-000125.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001919246-26-000125 |
| 2026-08-18 | 21:00 ET | [DEF 14A](/filings/0001919246-26-000120.md) | Proxy statement, period 2026-09-29 | 0001919246-26-000120 |
| 2026-08-13 | 11:20 ET | [10-Q](/filings/0001919246-26-000113.md) | Quarterly report, period 2026-06-30 | 0001919246-26-000113 |
| 2026-08-13 | 11:15 ET | [8-K](/filings/0001919246-26-000112.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000112 |
| 2026-08-13 | 11:06 ET | [10-Q/A](/filings/0001919246-26-000111.md) | Quarterly report, amended, period 2026-03-31 | 0001919246-26-000111 |
| 2026-08-13 | 11:00 ET | [8-K](/filings/0001919246-26-000110.md) | 4.02 Non-reliance on financial statements | 0001919246-26-000110 |
| 2026-05-28 | 21:01 ET | [8-K](/filings/0001919246-26-000085.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000085 |
| 2026-05-21 | 21:00 ET | [8-K](/filings/0001919246-26-000078.md) | 4.01 Change of auditor; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001919246-26-000078 |
| 2026-05-14 | 11:08 ET | [8-K](/filings/0001919246-26-000071.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000071 |
| 2026-05-14 | 11:06 ET | [10-Q](/filings/0001919246-26-000070.md) | Quarterly report, period 2026-03-31 | 0001919246-26-000070 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001919246-26-000013.md), filed Mar 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/fe3ab620-c9d1-42c7-879c-ff77dbd50e25)

## About the filer

- CIK: 1919246
- Tickers: PTHS
- Exchange: NYSE
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: NV
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.